Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase

Journal of Neuroscience Research

Volumn 54, Issue 5, 1998, Pages 691-697

  Xu, Yimei ^a,c   Stokes, Alan H ^a   Roskoski Jr , Robert ^b   Vrana, Kent E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dopamine; Parkinson's disease; Quinone; Tyrosinase; Tyrosine hydroxylase

Indexed keywords

ANTIOXIDANT; DOPA; DOPAMINE; MONOPHENOL MONOOXYGENASE; QUINONE DERIVATIVE; TYROSINE 3 MONOOXYGENASE;

ARTICLE; CATECHOLAMINE SYNTHESIS; DENATURING GRADIENT GEL ELECTROPHORESIS; ENZYME INACTIVATION; ENZYME MODIFICATION; GEL PERMEATION CHROMATOGRAPHY; IMMUNOPRECIPITATION; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; CHROMATOGRAPHY, GEL; DIHYDROXYPHENYLALANINE; DITHIOTHREITOL; DOPAMINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEEDBACK; GLUTATHIONE; MONOPHENOL MONOOXYGENASE; NAD; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PC12 CELLS; PLANT PROTEINS; PRECIPITIN TESTS; RATS; TYROSINE 3-MONOOXYGENASE;

EID: 0032403510     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F     Document Type: Article

References (36)

1. Almas B, Le Bourdelles B, Flatmark B, Mallet J, Haavik J (1992): Regulation of recombinant human tyrosine hydroxylase isozymes by catecholamine binding and phosphorylation. Structure/ activity studies and mechanistic implications. Eur J Biochem 209:249-255.
2. Andersson KK, Cox DD, Que L Jr, Flatmark T, Haavik J (1988): Resonance Raman studies on the blue-green-colored bovine adrenal tyrosine 3-monoxygenase (tyrosine hydroxylase). Evidence that the feedback inhibitors adrenaline and noradrenaline are coordinated to iron. J Biol Chem 263:18621-18626.
3. Andersson KK, Vassort C, Brennan BA, Que L Jr, Haavik J, Flatmark T, Gros F, Thibault J (1992): Purification and characterization of the blue-green rat pheochromocytoma (PC 12) tyrosine hydroxylase with a dopamine-Fe(III) complex. Reversal of the endogenous feedback inhibition by phosphorylation of serine-40. Biochem J 284:687-695.
4. Berman SB, Zigmond MJ, Hastings TG (1996): Modification of dopamine transporter function: Effect of reactive oxygen species and dopamine. J Neurochem 67:593-600.
5. Daubner SC, Lauriano C, Haycock JW, Fitzpatrick PF (1992): Site-directed mutagenesis of serine-40 of rat tyrosine hydroxylase: Effects of dopamine and cAMP-dependent phosphorylation on enzyme activity. J Biol Chem 267:12639-12646.
6. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989): Basal lipid peroxidation in substantia nigra is increased in Parkinson's Disease. J Neurochem 52:381-389.
7. Filloux F, Townsend JJ (1993): Pre-and post-synaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 119:79-88.
8. Gahn LG, Roskoski R Jr (1991): Tyrosine hydroxylase purification from rat PC12 cells. Prot Express Purif 2:10-14.
9. Graham DG (1978): Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
10. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF (1978): Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C 1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644-653.
11. Haavik J, Martinez A, Flatmark T (1990): pH-dependent release of catecholamines from tyrosine hydroxylase and the effect of phosphorylation of ser-40. FEBS Lett 262:363-365.
12. Hastings TG (1995): Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J Neurochem 64:919-924.
13. 3H] dopamine: Impact of ascorbic acid and glutathione. J Neurochem 63:1126-1132.
14. Hastings TG, Lewis D, Zigmond MJ (1996): Role of oxidation in the neurotoxic effects of nigrostriatal dopamine injections. Proc Natl Acad Sci USA 93:1956-1961.
15. Hirsch E, Graybiel AM, Agid YA (1988): Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 34:345-348.
16. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y (1992): Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's Disease related to their neuromelanin content? J Neurochem 59:1080-1089.
17. Kish SJ, Morito C, Hornykiewicz O (1985): Glutathione peroxidase activity in Parkinson's Disease brain. Neurosci Lett 58:343-346.
18. Kumer SC, Vrana KE (1996): Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67:443-462.
19. Laemmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
20. Lazar MA, Lockfeld AJ, Truscott RJW, Barchas JD (1982): Tyrosine hydroxylase from bovine striatum: Catalytic properties of the phosphorylated and nonphosphorylated forms of the purified enzyme. J Neurochem 39:409-422.
21. Levitt M, Spector S, Sjoerdsma A, Udenfriend S (1965): Elucidation of the rate-limiting step in norepinephrine biosynthesis in the perfused guinea-pig heart. J Pharmacol Exp Ther 148:1-7.
22. Marsden CD (1969): Brain melanin. In Wolman M (ed): "Pigments in Pathology." New York: Academic Press, pp 395-420.
23. Miranda M, Botti D, Bonfigli A, Ventura T, Arcadi A (1984): Tyrosinase-like activity in normal human substantia nigra. Gen Pharmac 15:541-544.
24. Nagatsu T, Levitt M, Udenfriend S (1964): Conversion of L-tyrosine to 3,4-dihydroxyphenylalanine by cell-free preparations of brain and sympathetically innervated tissues. Biochem Biophys Res Commun 14:543-549.
25. Nagatsu T, Mizutani K, Nagatsu I, Matsuura S, Sugimoto T (1972): Pteridines as cofactor or inhibitor of tyrosine hydroxylase. Biochem Pharmacol 21:1945-1953.
26. Okuno S, Fujisawa H (1985): A new mechanism for regulation of tyrosine 3-monooxygenase by end product and cyclic-AMP dependent protein kinase. J Biol Chem 260:2633-2635.
27. Okuno S, Fujisawa H (1991): Conversion of tyrosine hydroxylase to stable and inactive form by the end products. J Neurochem 57:53-60.
28. Perry TL, Godin DV, Hansen S (1982): Parkinson's Disease: A disorder due to nigral glutathione deficiency? Neurosci Lett 33:305-310.
29. 3H] tyrosine by charcoal. Life Sci 39:2185-2189.
30. Ribiero P, Wang Y, Citron BA, Kaufman S (1992): Regulation of recombinant rat tyrosine hydroxylase by dopamine. Proc Natl Acad Sci USA 89:9593-9597.
31. Rodgers AD, Curzon G (1975): Melanin formation by human brain in vitro. J Neurochem 24:1123-1129.
32. Sanchez-Ferrer A, Rodriguez-Lopez JN, Garcia-Canovas F, Garcia-Carmona F (1995): Tyrosinase: A review of its mechanism. Biochim Biophys Acta 1247:1-11.
33. Stokes AH, Brown BG, Lee CK, Doolittle DJ, Vrana KE (1996): Tyrosinase enhances the covalent modification of DNA by dopamine. Mol Brain Res 42:167-170.
34. Udenfriend S, Zaltzman-Nirenberg P, Nagatsu T (1965): Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol 14:837-845.
35. Vrana SJ, Azzaro AJ, Vrana KE (1992): Chronic selegiline administration decreases tyrosine hydroxylase mRNA and activity in the rat nigrostriatal pathway. Mol Pharmacol 41:339-344.
36. Xu Y, Stokes AH, Freeman WM, Kumer SC, Vogt BA, Vrana KE (1997): Tyrosinase mRNA is expressed in the substantia nigra of humans. Mol Brain Res 45:159-162.